A Virus-Agnostic Approach to Prophylactic Development
Ness Therapeutics Inc. is a biotechnology company focused on developing prophylactics that do not depend on virus or strain specificity, to address known respiratory viruses and those yet to emerge. The host-directed approach is being further explored toward applications beyond respiratory infections.
Led by Deep Scientific and Development Experience
Ness Therapeutics Inc. is led by founders who bring together world-class scientific expertise and deep biologics development experience. From fundamental immunology research to the practical realities of manufacturing and bringing a biologic to clinic.
- Dr. Fish is a leading academic in immunology and infectious diseases, recognized internationally for her scientific and policy contributions.
- She was appointed as a Member of the Order of Canada and a Tier 1 Canada Research Chair in Women’s Health & Immunobiology.
- Dr. Fish is a Professor in the Department of Immunology at the University of Toronto and Scientist Emerita at the Toronto General Hospital Research Institute at the University Health Network.
- She is a Fellow of the Canadian Academy of Health Sciences, the American Academy of Microbiology and the African Academy of Sciences.
- Dr. Fish has also served on the Expert Science Panel to the Chief Scientific Advisor to the Government of Canada, and the COVID-19 Therapeutics Task Force of the Government of Canada.
- Dr. Rahbar is a biopharmaceutical executive with extensive experience in therapeutic development, manufacturing, and technical strategy.
- He has nearly two decades of experience in process development, technology transfer, clinical manufacturing, and regulatory CMC for biologics, vaccine candidates, and nucleic acid-based products.
- Dr. Rahbar has held senior leadership roles in the sector and is recognized for his expertise in translational development across diverse platforms.
- He has also authored numerous peer-reviewed publications.
- At Ness Therapeutics Inc., Dr. Rahbar leads the company’s technical strategy and development programs.
Strengthening the Path to
Clinical Readiness
Ness Therapeutics Inc. is supported by experienced regulatory leadership to guide N001 through the IND/CTA process and toward clinical readiness.
- Dr. Snow is a strategic regulatory advisor with extensive experience in global biologics development and regulatory affairs.
- She has deep expertise in IND/CTA strategy, regulatory execution, and CMC strategy.
- She is recognized for her ability to align regulatory and technical strategy in ways that support efficient development timelines and reduce execution risk.
- At Ness Therapeutics Inc., Dr. Snow advises on the regulatory pathway for N001, helping de-risk development and support advancement toward clinical readiness.
A Focused and Disciplined Development Strategy
Ness advances its programs through a stepwise development strategy grounded in biological rationale, translational potential, and scalability. The company maintains a focused pipeline led by N001, with selective expansion into adjacent indications where the underlying biology supports further development.
Scientific board
Leading experts in airway biology, immunology, and infectious disease.
Emeritus Director and Distinguished Scientist - Recognized interferon expert.
President, Pacific Biopharma Pty Ltd.
Monash University, Faculty of Medicine, Nursing and Health Sciences.
Melbourne, Australia
CEO & Director, ALIGOS Therapeutics- Recognized for interferon - based antiviral drug development.
Former CEO, Alios BioPharma Inc. (acquired by Johnson & Johnson)
San Francisco, USA
Infectious disease specialist, medical microbiologist - Recognized as one of North America's leading COVID experts.
McGill University Health Centre. Montreal, Canada
Professor, Centre of Blood Research - Internationally recognized for proteinase proteomics.
University of British Columbia, Professor.
Canada Research Chair.
Vancouver, Canada
Professor, Microbiology & Immunology - Internationally recognized for microbiology & immunology expertise.
Stony Brook University, Professor.
Stony Brook, NY, USA
Head, Centre for Innate Immunity & Infectious Diseases - Recognized interferon expert.
Professor, Hudson Institute of Medical Research.
Melbourne, Australia
Associate Professor, Immunology & Pathobiology - Recognized and a leading Canadian expert on respiratory virus infections.
Associate Professor, Sunnybrook Health Sciences Centre.
Toronto, Canada
Group Leader, Biotechnology Unit - Internationally recognized for process development for production of biopharmaceuticals.
International Centre for Genetic Engineering & Biotechnology.
Trieste, Italy
Program and Company Updates
Sign up to receive updates on N001's development milestones, regulatory progress, and key program announcements as Ness Therapeutics Inc. advances toward clinical readiness.
